NMN/NR (Nicotinamide Mononucleotide/Riboside) Off-Label Uses With Evidence Levels

How NMN and NR Raise NAD+ Levels

Both NMN and NR serve as biosynthetic precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme required by over 500 enzymatic reactions. NR enters cells via equilibrative nucleoside transporters, then nicotinamide riboside kinases (NRK1/NRK2) phosphorylate it into NMN. NMN itself was long thought to require extracellular dephosphorylation to NR before cellular uptake, but the 2019 identification of the Slc12a8 transporter in murine gut tissue suggested a direct import pathway [1].

Once inside the cell, NMN is adenylylated by NMNAT enzymes to produce NAD+. That NAD+ feeds three major consumer families: sirtuins (SIRT1 through SIRT7), poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes [2]. Age-related NAD+ decline, estimated at roughly 50% between ages 40 and 60 in some tissue assays, is driven largely by rising CD38 activity and chronic low-grade inflammation. Replenishing NAD+ through exogenous precursors is the pharmacologic rationale behind every off-label use discussed below.

A key distinction: NR has a longer human trial record and retains its dietary supplement status in the United States. NMN lost that status after the FDA's November 2022 ruling tied to Metro International Biotech's investigational new drug application [3]. Clinicians prescribing NMN now operate in a regulatory gray zone, which affects sourcing, compounding, and patient counseling.

Insulin Sensitivity and Metabolic Health (Evidence Level: Moderate)

The single most cited human trial for NMN is the Yoshino et al. 2021 study in Science. In 25 postmenopausal women with prediabetes, 250 mg/day of NMN for 10 weeks increased skeletal muscle insulin signaling, measured by phosphorylated AKT and mTOR pathway intermediates in biopsy samples. Muscle insulin-stimulated glucose disposal improved by approximately 25% compared to placebo [4]. The trial did not show changes in fasting glucose, HbA1c, or body weight, suggesting the effect was tissue-specific rather than systemic.

For NR, a 2019 randomized trial in 40 obese men (1,000 mg twice daily for 12 weeks) found no change in insulin sensitivity by hyperinsulinemic-euglycemic clamp, the gold standard method [5]. The discordance between NMN and NR results may reflect dose, population, or tissue-specific pharmacokinetics. It also underscores that these two molecules, despite sharing a downstream metabolite, are not interchangeable in clinical effect.

Preclinical work is more strong. In high-fat-diet mouse models, long-term NMN administration (500 mg/kg/day) prevented age-associated weight gain and improved glucose tolerance, hepatic insulin sensitivity, and lipid profiles [6]. These doses, however, do not translate proportionally to human regimens.

Clinicians considering NMN for metabolic indications should note the Yoshino trial's small sample size and the absence of replication. Prescribing NMN 250 mg/day for prediabetic patients as an adjunct to lifestyle intervention is biologically plausible, but the evidence does not yet support it as a standalone metabolic therapy.

Cardiovascular and Vascular Aging (Evidence Level: Low-to-Moderate)

Martens et al. Published a 2018 crossover trial in Aging Cell that randomized 24 healthy middle-aged and older adults to NR 500 mg twice daily or placebo for six weeks. NR supplementation reduced systolic blood pressure by a mean of 3.2 mmHg and reduced aortic pulse wave velocity, a validated surrogate for arterial stiffness [7]. The blood pressure reduction, if confirmed in larger trials, would be clinically meaningful, as a sustained 3 mmHg systolic decrease is associated with roughly 5 to 8% lower stroke risk at the population level according to Lancet meta-analytic data [8].

A separate pilot (N=30) using NR 1,000 mg/day in stable heart failure patients (NYHA class II to III) showed no improvement in ejection fraction or six-minute walk distance at 12 weeks, though circulating inflammatory markers (IL-1β, IL-6, TNF-α) trended downward [9]. The study was not powered to detect a difference in clinical endpoints.

On the NMN side, cardiovascular-specific human data remains thin. A 2022 Chinese open-label study in older adults (N=66) reported improved walking endurance and lower-limb vascular function after NMN 300 mg/day for 60 days, but the lack of blinding limits interpretation [10].

The mechanistic case is stronger than the clinical case. NAD+ repletion activates SIRT1 and SIRT3, which deacetylate endothelial nitric oxide synthase and mitochondrial superoxide dismutase 2, respectively. In ApoE-knockout mice, NMN reversed age-related capillary rarefaction and improved cerebral blood flow [11]. Translation to humans awaits adequately powered, double-blind trials with hard cardiovascular endpoints.

Exercise Performance and Muscle Function (Evidence Level: Low-to-Moderate)

A 2022 randomized, double-blind trial published in the Journal of the International Society of Sports Nutrition enrolled 48 recreationally trained runners. Participants receiving NMN 600 mg or 1,200 mg daily for six weeks showed dose-dependent improvements in ventilatory threshold and time-to-exhaustion during cardiopulmonary exercise testing compared to placebo [12]. The high-dose group improved oxygen uptake at the ventilatory threshold by 5.3%. No changes in body composition were observed.

For NR, an eight-week trial in older adults (N=32) measured grip strength, gait speed, and chair-rise time. NR 1,000 mg/day did not improve any functional measure compared to placebo, though NAD+ metabolite levels in whole blood increased 2.7-fold [13]. The disconnect between biochemical NAD+ elevation and functional outcome is a recurring theme across the NR literature.

A possible explanation: skeletal muscle NAD+ content may depend on local NMN synthesis more than circulating NR delivery. Preclinical data supports this. Mice lacking the Slc12a8 NMN transporter in skeletal muscle show impaired exercise tolerance that NR supplementation does not rescue, whereas direct NMN administration does [14]. If this biology translates to humans, NMN may have a pharmacologic advantage over NR for muscle-specific endpoints.

Athletes and aging adults interested in NAD+ precursors for performance should understand that the effect sizes reported so far are modest, smaller than those achieved with creatine monohydrate or structured exercise programming.

Neuroprotection and Cognitive Aging (Evidence Level: Preclinical/Very Low)

No published randomized controlled trial has tested NMN or NR against a primary cognitive endpoint in humans. The preclinical signal, though, is consistent.

In Alzheimer's disease mouse models (APP/PS1 transgenic), NMN 500 mg/kg/day for 28 days reduced amyloid-beta plaque burden and improved Morris water maze performance [15]. NR similarly attenuated tau hyperphosphorylation in a P301S tauopathy model and preserved hippocampal synaptic plasticity [16]. Both effects correlated with restored NAD+/NADH ratios in brain tissue.

Human evidence is limited to a small unblinded Korean study (N=32) in which NMN 250 mg/day for 12 weeks improved scores on the Korean version of the Montreal Cognitive Assessment by an average of 1.4 points compared to baseline [17]. Without placebo control, practice effects alone could explain that magnitude of change.

"NAD+ depletion is a consistent feature of neurodegenerative disease tissue, but whether replenishing it changes disease trajectory in humans remains an open question," Dr. Charles Brenner, who first identified NR as a vitamin B3, noted in a 2020 interview with Cell Metabolism [2].

Clinicians should not recommend NMN or NR for cognitive decline or dementia prevention based on current evidence. The mechanistic rationale justifies ongoing research but not clinical use.

Reproductive Health and Fertility (Evidence Level: Preclinical Only)

NAD+ decline in oocytes has been linked to reduced quality during reproductive aging. A 2020 Cell Reports study demonstrated that NMN administration in aged mice (equivalent to approximately 35 to 40 human years) restored oocyte quality, increased ovulation rates, and improved live birth rates [18]. The effect was mediated by SIRT2-dependent improvements in spindle assembly checkpoint fidelity.

For male fertility, NR reversed spermatogenic failure in a mouse model of postchemotherapy gonadotoxicity, with treated animals recovering sperm counts to 78% of baseline versus 31% in controls [19].

No human fertility trial for either compound has been published. Given the regulatory complexity and the vulnerability of the patient population, off-label prescribing for fertility is premature. Reproductive endocrinologists should track the ongoing MIB-626 (a crystalline form of NMN under IND) trials, which may include fertility-related secondary endpoints.

Hepatic Steatosis and Liver Health (Evidence Level: Low)

A 2023 randomized trial (N=44) in Japanese adults with elevated ALT gave NMN 250 mg/day for 12 weeks. ALT levels decreased by an average of 12.4 U/L in the NMN group versus 3.1 U/L in placebo [20]. Hepatic fat fraction was not directly measured by imaging, so the mechanism behind the ALT reduction (true fat clearance versus reduced hepatocyte injury versus another pathway) is unclear.

Preclinical models are more definitive. NMN activates hepatic SIRT1, which deacetylates SREBP-1c and reduces de novo lipogenesis. In mice fed a Western diet, NMN 300 mg/kg/day for 17 weeks reduced hepatic triglyceride content by 50% compared to controls [6].

NR's hepatic data is more cautionary. A 2021 mouse study showed that high-dose NR paradoxically increased hepatic triglycerides in a methionine-choline-deficient diet model of NASH, possibly through increased NAMPT recycling driving a futile NAD+ cycle [21]. This finding has not been replicated but warrants attention before recommending NR for liver-specific indications.

Skin Aging and UV Protection (Evidence Level: Very Low)

NAD+ is consumed rapidly by PARPs during UV-induced DNA damage repair. Topical NMN in hairless mice reduced UV-induced skin thickening and 8-OHdG (a DNA damage marker) by 40% [22]. Oral NR (400 mg/day for 21 days) was tested in a small human photoprotection study (N=20) and showed no difference in minimal erythema dose compared to placebo [23].

The gap between topical and oral results likely reflects bioavailability. Systemic NAD+ elevation after oral dosing may not raise skin NAD+ sufficiently to impact UV repair kinetics. Until topical NMN formulations enter human trials, this remains a theoretical application.

Safety Across Off-Label Applications

Across published human trials, both NMN and NR have demonstrated acceptable tolerability. A 2022 dose-escalation study of NMN up to 1,200 mg/day for four weeks reported no serious adverse events and no clinically significant changes in liver enzymes, creatinine, or complete blood counts [24]. The most common side effects were mild nausea (8% of participants), flushing (5%), and abdominal bloating (4%).

NR carries a similar safety profile at doses up to 2,000 mg/day based on NIAGEN (the branded NR from ChromaDex) pharmacokinetic studies [25]. One concern specific to NR at high doses is methyl group depletion: NR catabolism generates nicotinamide, which is methylated by NNMT to N-methyl-nicotinamide for renal clearance. Sustained high-dose NR could theoretically deplete S-adenosylmethionine (SAMe) pools, though this has not been observed in trials up to 12 weeks.

Long-term safety data beyond 12 weeks does not exist for either molecule at supplemental doses. Patients using NMN or NR off-label should have baseline and periodic monitoring of liver function, renal function, and homocysteine levels (as a proxy for methyl donor status).

Grading the Evidence: A Summary Framework

Off-label applications fall into three tiers when graded by available human evidence. Tier 1 (moderate evidence from at least one RCT with a relevant primary endpoint): insulin sensitivity for NMN and blood pressure/arterial stiffness for NR. Tier 2 (low-to-moderate evidence from small RCTs or secondary endpoints): exercise performance for NMN, hepatic ALT reduction for NMN, and inflammatory markers in heart failure for NR. Tier 3 (preclinical or very low human evidence): neuroprotection, fertility, and skin aging for both compounds.

No application currently meets the threshold for strong clinical recommendation. Prescribers should communicate this hierarchy directly to patients, especially given the out-of-pocket cost of pharmaceutical-grade NMN (typically $60 to $150 per month) and the regulatory uncertainty surrounding its supplement status.

The next inflection point may come from the Metro International Biotech Phase II program studying MIB-626 (NMN) at 1,000 mg twice daily in older adults, with primary endpoints including physical function and insulin sensitivity. Results are expected by late 2026.